RedHill Biopharma Reported New Data From a Prespecified Analysis of All Oral Opaganib's P-II/III Study in Severely Ill Hospitalized COVID-19 Patients.
Shots:
- Opaganib improved the median time to viral RNA clearance by at least 4 days in a prespecified analysis of all P-II/III study patients with positive PCR at screening; median of 10 days for viral clearance in the opaganib arm vs. clearance median not reached by end of 14-day treatment in PBO arm
- Opaganib demonstrated 62% reduction in mortality in a post-hoc analysis of the P-II/III study which is provided to regulators as part of ongoing discussions on potential pathways to approval in multiple countries
- Opaganib is the 1st oral novel drug candidate to improve viral RNA clearance in patients with severe COVID-19 pneumonia and also provides clinical evidence which supports opaganib's potential antiviral activity
Ref: PR Newswire | Image: Redhill
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
